The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a greater substantial reduction in body weight and improve metabolic mark